DRAFT AGREEMENT FOR CLINICAL TRIALS Study Protocol n° [INSERT NUMBER] Center: [INSERT NUMBER]Clinical Trials Agreement • June 15th, 2022
The INSTITUTION and the SPONSOR are hereinafter individually referred to as “Party” and collectively referred to as the “Parties”.
INITIATION 2Clinical Trials Agreement • December 20th, 2023
CLINICAL TRIALS AGREEMENTClinical Trials Agreement • January 28th, 2022 • Indiana
THIS CLINICAL TRIALS AGREEMENT (hereinafter referred to as the “Agreement”), effective as of (hereinafter referred to as the “Effective Date”) is by and between , a corporation organized under the laws of the State of whose offices are located at , (hereinafter referred to as “Sponsor”); and the Trustees of Indiana University, an educational institution organized under the laws of the State of Indiana, whose address is Indiana University, Attn: Clinical Trials Office, 410 West 10th Street, 1020, Indianapolis, IN 46202 (hereinafter referred to as “Institution”). Sponsor and Institution may be referred to individually as “Party” or collectively as “Parties”.
BASED ONClinical Trials Agreement • July 11th, 1997 • Siga Pharmaceuticals Inc • Pharmaceutical preparations
CLINICAL TRIALS AGREEMENT MODEL INVOLVING MEDICINAL PRODUCTSClinical Trials Agreement • November 7th, 2020
[Name of the Sponsor’s legal representative] on behalf of [name of Sponsor -company/organisation/private individual - of the Clinical Trial] (hereinafter known as the “Sponsor”), whose registered office address is [full address], TIN no. [taxpayer identification number].
South Carolina Clinical Trials Agreement (Agreement) Agreement to Reduce Cancer Morbidity & Mortality in South CarolinaClinical Trials Agreement • August 25th, 2020 • South Carolina
Purpose of this Agreement The intent and purpose of this Agreement is to provide for insurance coverage for certain services related to cancer for those South Carolinians covered by the health benefit plans issued by the undersigned health insurers, health maintenance organizations, and self-insured governmental employers. The general area covered pursuant to the is Agreement is coverage of the routine patient care costs for persons participating in cancer clinical trials within South Carolina 1.0 Cancer Clinical Trials 1.0.1 Cancer Clinical Trials Covered Pursuant to this Agreement The parties to this Agreement agree that for all those insured, diagnosed with cancer, and accepted into a Phase II, Phase III, or Phase IV clinical trial for cancer, group health plan contracts, as defined in the Employee Retirement Income and Security Act of 1974, and self-insured governmental employers coverage issued by the undersigned that provide for hospital, medical, or surgical coverage i
Clinical Trials AgreementClinical Trials Agreement • December 20th, 2020 • District of Columbia
The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), recognizes the importance of the pharmaceutical industry in the clinical development of new anti-cancer agents. DCTD wishes to foster collaboration with industry whenever possible. As part of its mission to improve cancer care, DCTD shares with industry the important goal of defining the contribution of a new drug or biologic in the treatment of cancer. DCTD therefore recognizes and supports the need of a private sponsor to focus at the appropriate time on clinical trials which lead to a New Drug Application (NDA) or a Biologics License Application (BLA) since an NDA and a BLA, once approved, are the vehicles through which new anti-cancer therapies become widely available to cancer patients. Thus DCTD considers it appropriate for the investigators sponsored by DCTD to do clinical trials of interest to, and partially supported by a pharmaceutical firm, provided that the trials have scientific merit a
Contract No DSTL/AGR/00256/01 BetweenClinical Trials Agreement • October 9th, 2013
Contractor:Simbec Research Limited Merthyr Tydfil Industrial Park Cardiff RoadMerthyr Tydfil CF48 4DR Defence Science and Technology Laboratory, Porton Down CONTRACT/TENDER NO: DSTL/AGR/00256/01 SCHEDULE OF REQUIREMENTS FOR Issued on: 2nd October 2013 Clinical Trials for a New Drug Product in Accordance with ICH Good Clinical Practice Previous Contract No (Renewal Cts Only) Table I – Requirements ITEM NO DESCRIPTION QTY FIRM PRICE£ (VAT EX) 1 ObjectiveThe Defence Science & Technology Laboratory (Dstl), acting on behalf of the United Kingdom’s Secretary of State for Defence is heading a group containing the Department of National Defence of Canada and the Minister of Defence of the Kingdom of the Netherlands to conduct clinical trials for a new drug product to ICH Good Clinical Practice. 2 Tasks Task A. Conduct the set up activities defined in the Contractors quotation reference RD209/25471A (Issue I) and in accordance with the Contractors Tender Proposal for provision of Clin
INITIATION 2Clinical Trials Agreement • January 7th, 2019
CONTRACT FOR CLINICAL TRIALS HOSPITAL UNIVERSITARI GERMANS TRIAS i PUJOLClinical Trials Agreement • February 8th, 2021
On the one hand, Dr Jordi Ara del Rey, with National ID Card No. 40983039-Y, the Territorial Manager of Metropolitana Nord on behalf of the Site Hospital Universitari Germans Trias i Pujol, with head office at Crta. de Canyet, s/n, 08916, Badalona, and Tax ID No. Q-5855029-D (hereinafter, the HOSPITAL),
ContractClinical Trials Agreement • July 28th, 2014
Florida Clinical Trials AgreementClinical Trials Agreement • November 8th, 2013
The undersigned parties to this Florida Clinical Trials Agreement (Agreement) acknowledge that Florida ranks higher than the national average in the incidence and mortality of cancer. The undersigned parties to this Agreement acknowledge that cancer is a leading cause of death in Florida. The parties further acknowledge that many cancers can be treated successfully if detected early. The undersigned health insurers, health maintenance organizations, and self-insured governmental employers have a compelling interest in improving the methods of cancer detection, treatment, and prevention.
CLINICAL TRIALS AGREEMENTClinical Trials Agreement • August 15th, 2017 • Ontario
CONTRACT FOR PERFORMANCE OF CLINICAL TRIALS WITH MEDICAL DEVICES: “ ”Clinical Trials Agreement • August 3rd, 2022
Of the one part, Mr./Ms. ………………………………………………… and ………………………………………………… Respectively acting in the name and on behalf of ………………………..………. (hereinafter, the SPONSOR), with registered office at ………………………..………., being empowered for this act by deed of power of attorney No ………………………..………., duly registered at the ………………………..………. Companies Registry, executed before the Notary of the ………………………..………. Notarial Association, Mr./Ms. ………………………..………., dated ………………………..………. .
INTRODUCTIONClinical Trials Agreement • March 28th, 2003 • Vion Pharmaceuticals Inc • Biological products, (no disgnostic substances) • District of Columbia
